BioLife Solutions Stock Forecast, Price & News

BioLife Solutions' stock was trading at $12.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BLFS stock has increased by 193.1% and is now trading at $35.91.
View which stocks have been most impacted by COVID-19.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for BioLife Solutions or view MarketBeat's top 5 stock picks.

Wall Street analysts have given BioLife Solutions a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioLife Solutions wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

BioLife Solutions is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for BioLife Solutions.

BioLife Solutions, Inc. (NASDAQ:BLFS) issued its quarterly earnings results on Wednesday, March, 11th. The medical equipment provider reported $0.02 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.02) by $0.04. The medical equipment provider had revenue of $8.30 million for the quarter, compared to analyst estimates of $8.72 million. BioLife Solutions had a return on equity of 0.53% and a net margin of 12.67%.
View BioLife Solutions' earnings history.

10 analysts have issued 1-year price targets for BioLife Solutions' shares. Their forecasts range from $17.00 to $40.00. On average, they expect BioLife Solutions' stock price to reach $30.22 in the next year. This suggests that the stock has a possible downside of 15.8%.
View analysts' price targets for BioLife Solutions.

Some companies that are related to BioLife Solutions include CONMED (CNMD), CONMED (CNMD), Outset Medical (OM), LivaNova (LIVN), InMode (INMD), Natus Medical (NTUS), ViewRay (VRAY), AxoGen (AXGN), Semler Scientific (SMLR), Zynex (ZYXI), Zynex (ZYXI), Cutera (CUTR), TransMedics Group (TMDX), Stereotaxis (STXS) and Stereotaxis (STXS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Canopy Growth (CGC), Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

BioLife Solutions' stock is owned by a variety of retail and institutional investors. Top institutional investors include Wasatch Advisors Inc. (5.37%), BlackRock Inc. (3.47%), Royce & Associates LP (2.64%), Gagnon Securities LLC (1.27%), Sentinel Pension Advisors Inc. (0.80%) and State Street Corp (0.64%). Company insiders that own BioLife Solutions stock include Aby J Mathew, Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Johan Wedell-Wedellsborg, Joseph C Schick, Karen A Foster, Marcus Schulz, Michael Rice, Raymond W Cohen, Thomas Girschweiler, Todd Berard and Walter Villiger.
View institutional ownership trends for BioLife Solutions.

BLFS stock was sold by a variety of institutional investors in the last quarter, including Sentinel Pension Advisors Inc., Cadence Capital Management LLC, Candriam Luxembourg S.C.A., Mesirow Financial Investment Management Inc., Signaturefd LLC, Cowen Prime Services LLC, Acuitas Investments LLC, and Acuitas Investments LLC. Company insiders that have sold BioLife Solutions company stock in the last year include Aby J Mathew, Greef Roderick De, James Mathers, Karen A Foster, Marcus Schulz, Michael Rice, Raymond W Cohen, Thomas Girschweiler, Todd Berard, and Walter Villiger.
View insider buying and selling activity for BioLife Solutions.

BLFS stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., BlackRock Inc., Gagnon Securities LLC, Ziegler Capital Management LLC, Royce & Associates LP, Iron Triangle Partners LP, Charles Schwab Investment Management Inc., and Gagnon Advisors LLC.
View insider buying and selling activity for BioLife Solutions.

Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BLFS stock can currently be purchased for approximately $35.91.

BioLife Solutions has a market capitalization of $1.18 billion and generates $27.37 million in revenue each year. The medical equipment provider earns $-1,660,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. BioLife Solutions employs 54 workers across the globe.

The official website for BioLife Solutions is www.biolifesolutions.com.

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider can be reached via phone at 425-402-1400 or via email at [email protected]